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Abstract 
Yam (Dioscorea spp.) and its associated extracts have been shown to possess a variety of biological 
activities and identified as beneficial in the control of glycaemia in patients with Type II Diabetes 
Mellitus (T2DM). The objective was to conduct a systematic search of the literature to investigate 
whether yam and its extract can improve glycaemia and whether consumption of yam could be 
beneficial for managing T2DM.  Using the PRISMA guidelines and the PICO framework, three 
databases (PubMed, Scopus, and Web of Science) were searched using a key term strategy. Strict 
inclusion criteria were employed to identify all relevant and available studies. The quality of these 
studies was assessed using SYRCLE’s Risk of Bias tool. Ten studies were included; and all studies 
consisted of findings from rodent models of diabetes, including animals consuming high fat diets or 
genetic models of diabetes. All ten studies showed that consumption of yam and/or its extract 
(containing dioscin, dioscorin, diosgenin, DA-9801/02, or Chinese yam polysaccharides) improved 
glycaemia.  These included improvements in fasting blood glucose and reductions in glucose and 
increase in insulin levels following a glucose tolerance test. Furthermore, significant changes in 
body weight and adiposity were observed in nine studies, these included improvements in lipid 
biomarkers in four and reductions in inflammatory markers in one. The current work indicates that 
the consumption of yam or its extracts can be beneficial for improving blood glucose however the 
molecular mechanism for these effects remain largely unknown. Future trials on human subjects are 
warranted. 
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Diabetes Mellitus (DM) is a non-communicable metabolic disease projected to affect 366 million by 
2030 (Saeedi et al. 2019; IDF 2019; Wild et al. 2004). The most common form of diabetes is Type II 
diabetes (T2DM) which often begins with obesity associated with insulin resistance and glucose 
tolerance leading to hyperglycaemia, impaired β-cell function, and a decrease in insulin secretion 
(Colledge et al. 2010). Furthermore, impairment in lipid and lipoprotein metabolism, increase 
oxidative stress, diminished vascular endothelial function and high blood pressure are also common 
in T2DM (Erion et al. 2016; Dhananjayan et al. 2016). Chronic exposure to these complications 
often leads to health conditions including peripheral neuropathy, retinopathy, and nephropathy 
alongside an increased mortality rate (Constantino et al. 2013).  
 
Therefore, controlling blood glucose is important to prevent diabetic complications and to improve 
health of patients.  While a number of hypoglycaemic agents have been developed, based on current 
understanding of the pathophysiology of T2DM, their use results in a myriad of side effects and the 
initial improvements in glycaemia are usually not sustained (Haak et al. 2017; Giorgino et al. 2005). 
 
Obesity is a risk factor for the development of T2DM, and dietary management is thought to reduce 
the burden on islet cells and thus improve glucose levels, inflammation, and lipid profile (Wu et al. 
2014).  Recent evidence suggests that the regular consumption of foods with bioactive compounds 
may benefit health related to prevention or management of chronic diseases (Samtiya et al. 2021; 
Rinaldo 2020; Mirmiran et al. 2014).   
 
Yam (Dioscorea), an angiosperm (flowering plant) not botanically related to sweet potato (Ipomoea), 
is commonly consumed in the Asian and African continents (FAO 2018). In the African populations, 
the prevalence of T2DM is ranges from 3.5% in rural area to 7.5% in urban area (Uloko et al. 2018; 
Gatimu et al. 2016). In Asia, yam has been used in Traditional Chinese medicine (TCM) as a natural 
medicine for T2DM (Jia et al. 2003).  
 
Of particular interest in this region are the numerous extracts, which include allantoin, dioscorin, 
sapogenins, prosapogenin, gracillin, choline, L-arginine, polysaccharides and proteins. Several in 
vitro and in vivo studies have highlighted the anti-diabetic action of a number of these extracts, 
including dioscorea ethanol extract (Maithili et al. 2011), total saponins (Guo et al. 2016; Yu et al. 
2015; Niu et al. 2010, McAnuff et al. 2005) allantoin (Go et al. 2015; Amitani et al. 2015), water 
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al., 2014; Ghosh et al. 2012).  However, many of these studies have been conducted in animal 
models in which diabetes was induced by streptozotocin (STZ) (Guo et al. 2016; Yu et al. 2015; Niu 
et al. 2010; McAnuff et al. 2005) or alloxan (Estiasih et al. 2018; Maithili et al. 2011).  These are 
popular methods but induce hyperglycaemia via the destruction of the pancreatic islets and does not 
mimic the insulin resistance presented in human patients with T2DM (Islam et al. 2012).  
 
Therefore, we conducted a systematic review to search the literature to investigate whether yam and 
its extract can improve glycaemia in diet-induced and spontaneous T2DM in vivo models and 
determine whether the consumption of these could be a diet modification.  
Method 
The review was constructed in accordance with the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) guidelines (Moher et al. 2015). 
 
Searching Strategy  
A computerised search of the literature was performed using three databases (PubMed, Scopus and 
Web of Science) between April 2020 and June 2020.  The searching process followed the Population 
(P), Invention (I), Comparison (C) and Outcome (O; PICO) framework.  The population was T2DM 
animal models or human patients diagnosed with T2DM, the intervention was yam or yam extracts in 
comparison to controls who do not receive the intervention and the measuring the outcome is the 
effect of the yam intervention on complications associated with T2DM such as insulin sensitivity and 
glucose tolerance.  Search of terms was conducted through the literature to define the keywords; yam  
OR  "yam extract"  OR  Dioscorea  AND  diabetes  OR  antidiabet*  OR  glycaem*  OR  insulin  OR  
glucose  OR  T2DM. Two independent reviewers (WA & AM) assessed the titles, abstracts, and full 
articles, based on strict inclusion and exclusion criteria, any disagreements with the section of the 
article were resolved through discussion.  Full articles of the selected titles were retrieved and the 
reference lists of these were searched to identify any additional publications. 
 
Selected Studies Criteria 
All related articles from inception were considered as there have been no previous systematic 
reviews conducted to investigate the relationship of yam and its phytochemicals to the anti-diabetic 
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 Only articles written in English were eligible to avoid any misleading translations.  
 All studies must have described either animal models with diet induced T2DM or human 
participants who have been diagnosed with T2DM by a medical profession. 
 Any Yam and yam extracts were considered. 
 All studies must have a measure of glycaemic parameters.  
 Randomised Clinical Trials (RCT). 
 Fully published studies. 
Exclusion criteria  
 Chemically induced hyperglycaemia using pharmaceutical agents (e.g., streptozotocin) 
 Non-diabetic model.  
 In vitro cell studies exploring the cellular mechanisms. 
 Systematic Reviews or critical reviews. 
 TCM or any traditional medicine that contains other plants in addition to or alternative to Yam. 
 
Measured Outcomes 
The primary outcomes of this review are the effect on glycaemic parameters such as fasting blood 
glucose (FBG), haemoglobin A1c (HbA1c), glucose tolerance test (GTT), insulin levels, homeostatic 
model assessment of insulin resistance (HOMA-IR), insulin-glucose ratio (IGR), insulin sensitivity 
index (ISI), insulin tolerance test (ITT), metabolic clearance rate (MCR) and adiposity insulin 
resistance index (Adipo-IRI). While secondary measurements were factors associated with 
glycaemic control. These include body weight, lipid profile (total fat (TF), white adipose tissue 
(WAT), total cholesterol (TC), triglyceride (TG), low (LDL) and high(HDL) - density lipoprotein 
and Free Fatty Acids (FFA)), blood pressure (Systolic (SBP) and diastolic (DBP)) and inflammatory 
parameters (leptin, interleukin (IL) – 1β, IL-10, Matrix metalloproteinase (MMP), Nuclear factor 
kappa B (NF-β)). 
 
Data extraction 
A standard data extraction form as used to obtain data from the studies and charted using Excel 
(Microsoft excel, Washington, USA). Data extracted included title, author, publication year, country, 
study population, sample size, diabetic model, exposure to yam genus or yam extracts and outcomes 
(FBG, HbA1c, glucose levels following GTT, insulin levels, HOMA-IR, MCR and Adipo-IRI), body 
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DBP), and inflammatory parameters (leptin, IL-1β, IL-10, MMP, NF-β)). The results from each 
study alongside statistical outcomes were also extracted.   
 
Data analysis  
The relevant results were expressed in tables. The key characteristics of the selected papers included 
the study design, population, model used, number of the sample, outcome measures and doses of 
intervention groups. The significant effects in repose to the intervention was charted to compare 
across the article retrieved. Raw values for the primary outcome measures were not reported 
consistently across all studies; therefore, we were unable to compare the magnitude of the effect on 
the primary outcome measures and conduct a meta-analysis. 
 
 
Quality Assessment  
The SYRCLE’s Risk of Bias (RoB) tool was used to assess quality assessment due to the lack of 
human participant studies. This is an adapted version of the Cochrane RoB tool (Higgins  et al. 2011) 
consisting of 10 items relating to 6 types of bias.  Items 1, 3, 8, 9, 10 are adopted from the Cochrane 
RoB tool while items 2, 4, 5, 6, 7 have been adapted or replaced to allow for appropriate assessment 
of animal studies (Hooijmans et al. 2014; Table S1). Signalling criteria were used to determine and 
assign a judgement of low, high, or unclear risk of bias.   
 
The quality assessment examined multiple types of bias; selection, performance and direction, 
attrition and reporting. Selection bias (Items 1,2,3) was assessed by sequence generation, baseline 
characteristics and allocation concealment. Performance bias (item 4 ,5) was assessed by randomised 
housing and blinding relating to researchers and/or animal caregivers. Detection bias (item 6, 7) 
assessed any random outcome assessment and blinding as it can lead to multiple types of bias. 
Attrition bias (item 8) was explored by assessing incomplete outcome data while reporting bias (item 
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Eligibility of studies  
Using three electronic databases (PubMed/Medline, Scopus and WoS), we identified 967 papers 
published between 1962 to April 2020. Following the removal of duplicates and an initial title screen, 
215 studies were assessed in more detail. Of these 58 were evaluated against stringent 
inclusion/exclusion criteria; 34 used medically induced diabetic models, 7 utilised a mixture of 
compounds which contained extracts from sources other than yam, 7 did not measure glucose levels 
and 4 did not include yam. This left 10 studies eligible for inclusion (Figure 1). 
 
Quality assessment  
All 10 papers had ‘Fair’ as a final judgement for quality (Table 1 and S1). Based on the assessed bias 
criteria, Moon et al. (2014) was the only study that scored ‘High Risk’ at the ‘Selection Bias’ 
questions 1, 2, 3. While ‘Performance and Detection bias’ questions 4 and 6 had unclear and low risk 
in all studies, question 5 and 7 which assess the blinding for caregiver and investigators were judged 
as ‘High Risk’; however, this may not affect the overall judgement where Hirst et al. (2014) found in 
their meta-analysis that blinding in animal trials is not statistically significant. In regard to ‘Attrition 
Bias’, question 8 highlighted two papers as ‘High Risk’ which are Xu et al. (2020) where eight out of 
10 mice outcomes data were reported and Cheng et al. (2019) where eight out of 14 mice outcomes 
data were reported.  
 
Study Characteristics 
The characteristics of the studies are summarised in Table 2.  The selected studies were located in 
Asian countries, though no restraints were placed on location. The experimental length varied from 4 
weeks to 19 weeks with an average of 11 weeks. No studies included human participant diagnosed 
with T2DM, all studies were carried out in rodent model, although two studies utilised in vitro 
models as part of their study design (Xu et al. 2020; Moon et al. 2014).  In the rodent model T2DM 
was induced by consuming high fat diet (HFD) in rats or mice, the KK-A
y
 mice, which 
spontaneously exhibit T2DM and the db/db mice, a genetic model of T2DM were fed HFD, while 
the OLETF mice fed normal diet; one study, Hsu et al. (2007) fed the rodent model rats with high 
fructose diet to induce hyperglycaemia.  The studies utilised a variety of Dioscorea species although 
two studies (Li et al. 2019; Shih et al. 2015) did not mention the yam species. A variety of yam 
extracts were used in nine of the studies; these included components, Dioscin (Xu et al. 2020; Li et al. 
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and DA-9802 (Moon et al. 2014; Kim et al. 2012) and Dioscorea esculenta powder (Sato et al. 
2017); while one study used raw material of Dioscorea Oppesita, (a synonym of two species of yam 
Discorea polystachya and Dscorea oppositifolioa)  (Hsu et al. 2007).  The yam and/or extracts were 
obtained via various methods; five articles reported their extraction methods from raw yam (Xu et al. 
2020; Moon et al. 2014; Kim et al. 2012; Cheng et al. 2019; Wu et al. 2018) while two articles 
purchased the yam from external sources (Hashidume et al. 2018; Hsu et al. 2007).  The extraction 
methods included aqueous ethanol extraction from dried yam (Xu et al. 2020; Moon et al. 2014; Kim 
et al. 2012), water extraction and alcohol precipitation method (Cheng et al. 2019) and raw flush 
sample mixed with Tris buffer and purified with DE-52 ion exchange chromatography (Wu et al. 
2018). These were administered either orally or with saline through gavage at varying doses ranging 
from 5mg/kg to 100mg/kg. Biochemical measurements included measurements of glycaemia (FBG, 
GTT, HbA1c, HOMA-IR, IGR, ISI, ITT, MCR and adipo-IRI), lipid profile (TF, WAT, TC, TG, 
LDL and HDL and FFA), blood pressure (SBP and DBP) and inflammatory markers (leptin, IL-1β, 
IL-10, MMP, NF-β; Table 3 and 4). 
 
Effects of yam extract on measurements of glycaemia  
FBG/GTT 
All the included studies measured glucose and, although these were measured via a variety of 
methods (FBG/GTT), they all showed that treatment with either yam or its extract led to significant 
improvements in glucose tolerance compared to the controls (Table 2). FBG was reported in all 
studies except Wu et al. (2018) and Shih et al. (2015), while GTT was measured in five of the ten 
studies (Xu et al. 2020; Wu et al. 2018; Shih et al. 2015; Kim et al. 2012; Hsu et al. 2007). Dioscin, 
dioscorin, DA-9801, DA-9802, Diosgenin and CYP improved FBG (P<0.05), while dioscin, 
dioscorin, DA-9802 were shown to improve GTT from 30 minutes to 120 minutes after oral or 
intraperitoneal glucose load (P<0.05). The lowest working doses of yam or yam extract ranged from 




db/db, OLEFT) the 
lowest working doses ranged from 0.5-30mg/kg (Table 3).   
 
HbA1c 
HbA1c was measured in two of the ten studies (Xu et al. 2020; Hsu et al. 2007); both showed that 
consumption of yam or its extract significantly reduced HbA1c.  Xu et al. (2020) showed that dioscin 
reduced HbA1c in KK-A
y 
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no effect on FBG. While Hsu et al. (2007) showed that consumption of D. Opposita Thunb had a 
significant reduction (P<0.05) (Table 3) 
 
Insulin  
Fasting insulin levels were measured in three of the ten papers (Xu et al. 2020; Li et al. 2019; Kim et 
al. 2012) and all showed significant decrease insulin in a dose dependant manner (P<0.05; Table 3).  
HFD mice treated with Dioscin (10 and 20mg/kg) (Li et al. 2019) or DA-9082 (100mg/kg) (Kim et al. 
2012) reduced fasting insulin levels in HFD mice.  Dioscin also significantly reduced fasting insulin 
levels in KK-A
y 
mice at all three doses 20, 40 and 80mg/kg (Xu et al. 2020). 
 
HOMA-IR, ISI, ITT, IGR, MCR 
HOMA-IR was measured in two of the ten studies (Xu et al. 2020; Li et al. 2019), while ISI was 
measured in one (Xu et al. 2020), ITT was measured in two (Xu et al. 2020; Cheng et al. 2019), IGR 
was measured in one (Kim et al. 2012) and MCR was measured in one (Sato et al.  2017; Table 3).  
Administration of the dioscin in HFD mice and KK-A
y 
significantly reduced HOMA-IR, ISI and 
glucose following an ITT at all three doses (20-80mg/kg) (Xu et al. 2020), HOMA-IR in Li et al. 
(2019) reduced in 10, 20mg/kg dioscin groups. While administration of diosgenin in OLEFT mice 
significantly increased MCR (Sato et al. 2017) and DA-9802 in Kim et al. (2012) reduced IGR 
significantly. ITT in Cheng et al. (2019) was significant in CYP 20mg/kg. 
 
Adipo-IRI 
One study measured adipo-IRI (Li et al. 2019) and showed that dioscin treatment (5-10mg/kg) 
resulted in significant reduction. (P<0.05). 
 
Other Factors Related to Glycaemic Control 
Body weight Changes, Total fats, White adiposity tissue and Adiposity index 
Nine of the ten studies measured body weight; of these four (Xu et al. 2020; Cheng et al. 2019; Li et 
al. 2019; Wu et al. 2018) observed a significant decrease in body weight regardless of diabetic model 
(HFD, KK-A
y
 or C57BL/6) or yam extract (dioscin, CYP, dioscorin; P<0.05).   Li et al. (2019) found 
that the decrease in body weight following dioscin treatment (10-20mg/kg) was due to a 14% 
decrease in total fat (p<0.05). However, Hashidume et al. (2018), Sato et al. (2017), Shih et al. 
(2015), Moon et al. (2014) and Kim et al. (2012) did not observe any changes in body weight nor 
changes in white adiposity tissue following treatment with sanyaku, diosgenin, dioscorin, DA-9801 
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Lipid Profile (TC, TG, LDL, HDL and FFA) 
Five studies (Xu et al. 2020; Li et al. 2019; Cheng et al. 2019; Wu et al. 2018; Hashidume et al. 
2018) measured the lipid profile biomarkers, these included TC, TG, LDL, HDL and FFA (Table 4), 
of these, four found changes in some lipid biomarkers, only Hashidume et al. (2018) observed no 
differences between treatment and control. Xu et al. (2020), and Li et al. (2019) revealed significant 
reductions in TC, TG, LDL and FFA following dioscin and treatment (P<0.05) in both KK-A
Y
 and 
HFD diet mice. These results were partially supported by Wu et al. (2018) and Cheng et al. (2019), 
while they observed significant reduction in TC and LDL following dioscorin and CYP treatment 
respectively in HFD model, no changes in TG were observed.  In addition, both Xu et al. (2020) and 
Cheng et al. (2019) found that dioscin and CYP also increased HDL levels.  
 
Blood Pressure  
Systolic (SBP) and diastolic (DBP) blood pressure was measured in only one of ten studies.   Shih et 
al. (2015) showed a significant decrease in SBP (P <0.05), but not DBP (Table 4)  
 
Inflammatory markers 
One of the ten studies measured markers of inflammation and adipocytokines, these included leptin, 
IL1β, IL-10, MMP and NFB.  Cheng et al. (2019) showed that administration of CYP induced a 
significant decreased all the markers suggesting an anti-inflammatory effect of CYP (Table 4). 
Discussion 
The number of people suffering from T2DM is increasing worldwide and has become a global public 
health problem. New treatment strategies are increasingly needed, and many studies have indicated 
that natural food constituents, such as resistance starch and bioactive compounds (e.g. 
phytochemicals), could be incorporated into a healthy balanced diet to aid in the prevention or 
management of T2DM.  
 
Yam (Dioscorea spp.) is the fourth most important tuber crop after potatoes, cassava and sweet 
potatoes and contains a good source of essential dietary supplements such as protein, well-balanced 
essential amino acids, and many dietary minerals (Padhan et al. 2020; Zhang et al. 2014).  Recently 
interest has focused on yam as a potential insulin mimetic, thus we searched the current literature to 
investigate whether yam and/or its extracts has the potential to help manage T2DM. We observed 
that consumption of yam and/or its extracts had a beneficial effect on numerous glycaemic 
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extracts helped improvements in adiposity and circulating lipids, which are known to influence the 
development of T2DM.  
 
However much of the work conducted on the effects of yam on T2DM has been shown in animal 
models and therefore further research is required in human participants, although Jimoh et al. (2008) 
has shown that consumption of brown yam flour improved glycaemia in healthy subjects compared 
to other yam flours. In this review, we focused on studies conducted in models in which T2DM was 
induced by diet or in animals genetically predisposed to developing T2DM rather than those in which 
diabetes was induced by an injection of STZ, which is a model of type 1 diabetes. High fat feeding in 
mice leads to obesity, hyperinsulinemia and altered glucose homeostasis due to insufficient 
compensation by islets, thus modelling the human situation more accurately (King 2012), while STZ 
administration damages pancreatic β-cells depicting type 1 diabetes (Graham et al. 2011). However, 
we also included rodent models in which T2DM develops spontaneously this included the OLEFT 
model, in which animals inherit diabetes, KK-A
Y
 mice that develop obesity and severe 
hyperinsulinemia (Tomino 2012), again mimic human predisposition to diabetes.  Furthermore, in 
these models insulin sensitivity can be reversed via dietary manipulation and/or pharmacological 
administration as well as enable us to understand possible mechanisms (Tomino 2012).   
 
All papers identified in this review showed that consumption of yam and/or extract at various doses 
improved glycaemia by improving fasting glucose levels and insulin sensitivity. As mentioned earlier 
starch is the most abundant component of yam; cooking alters the properties of the starch making it 
more resistant to digestion. Resistant starch has been shown to prevent hyperglycaemia and reduce 
the risk of diabetes, (Rinaldo 2020; Raigond et al. 2015; Birt et al. 2013) and lower serum 
triglycerides and LDL cholesterol due to reduction in fat absorption (Nishimura et al. 2011; Shujun 
et al. 2008). However, all studies identified in this review used extracts to treat the rodents, thus it is 
unlikely that an increase in resistance starch was responsible for the observed effects, but does 
highlight that consumption of yam or its extract has similar effects on glycaemia. 
 
Another possible reason for the observed improvements in glycaemia maybe due to the inhibition of 
-glucosidase; indeed yam and its extracts have been shown to be potent inhibitors of this enzyme 
(Ghosh et al. 2014; Zhang et al. 2011).  -glucosidase is located on the brush border of the small 
intestine and breaks down starch to glucose, and many -glucosidase inhibitors, such as quercetin 
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2015; Ma et al. 2010; Kado et al. 1998; Vasselli et al. 1993). Not only do these inhibitors reduce 
fasting blood glucose (Van De Laar et al. 2005) they also reduce postprandial hyperglycaemia thus 
reducing Hb1Ac (Padhi et al. 2020). However, only two of the eight studies measured this, but both 
found significant decreases (Xu et al. 2020; Hsu et al. 2007). These inhibitors can also influence the 
release of the incretin glucagon like peptide 1 (GLP-1), in support Go et al. (2015) showed that 
allantoin (a yam extract) can increase GLP-1 release in a rat model of streptozotocin induced 
diabetes. Indeed, we found that yam and/or extract treatment led to a decrease in plasma insulin in 
the three studies, which measured insulin levels (Xu et al. 2020; Li et al. 2019; Kim et al. 2012).  
Furthermore, these inhibitors can reduce lipid deposition and reduce adipocyte size and TG and LDL 
(Go et al. 2015; Kado et al. 1998; Vasselli et al. 1993); indeed, we observed reductions in TG, LDL, 
FFA and TC in five of the ten studies (Xu et al. 2020; Li et al. 2019; Cheng et al. 2019; Wu et al. 
2018; Hashidume et al. 2018). Thus, further supporting the notion that consumption of yam and/or 
extracts results in the inhibition of -glucosidase to exert its effects.  However, the potency of 
inhibition of -glucosidase by yam and/or its extract is dependent on the solvent used for extraction 
(Ghosh et al. 2014; Zhang et al. 2011) and may be one of the reasons why there was difference in the 
lowest working dose observed in the studies, even when the same yam extract was utilised. Indeed 
Xu et al. (2020) used sodium carboxymethyl cellulose, while Li et al. (2019) used saline to dissolve 
dioscin. 
Other modes of action that yam and/or its extracts could improve glycaemic parameters is via the 
amelioration of oxidative and inflammatory responses.  Consumption of high fat diets and high lipid 
profile levels can lead to the development of oxidative stress and systematic inflammation (Tan et al. 
2019), which results in decreased insulin sensitivity leading to hyperinsulinemia and hyperglycaemia 
causing a pre-diabetic state. If uncontrolled, this can hinder the ability of the β-cells to meet demand 
leading to the development of diabetes (Manna et al. 2015). This further exacerbates oxidative stress 
and inflammation leading to complications such as hypertension (Ormazabal et al. 2018). Numerous 
studies support the notion that yam and/or its extracts have antioxidant and anti-inflammatory 
properties (Chiu et al. 2013; Jin et al. 2011; Jin et al.  2010) 
 
Indeed, we found that treatment with CYP was found to decrease pro-inflammatory markers NF-Kβ, 
MMP-3, IL-1B, and anti-inflammatory marker IL-10 (Cheng et al. 2019). IL-10 increases with 
obesity to protect against the disruption of insulin signalling, thus Cheng et al. (2019) concluded that 
CYP acted to reduce pro-inflammatory cytokines rather than stimulate anti-inflammatory cytokines. 
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factor-alpha (TNF-), monocyte chemoattractant protein-1 (MCP-1) and IL-6 in obese rodents (Gil 
et al. 2015). In addition, the levels of peroxisome proliferator-activated receptors  (PPAR) 
coactivator 1 (PGC-1) in the pancreas return to basal expression levels in those animals of normal 
weight, similar to the effects of the drug metformin (Ma et al. 2020). PGC-1 deficiency in the 
pancreas leads to an increase in pro-inflammatory markers production via NF-B, which in turn can 
lead to further damage of the pancreatic tissue (Rius-Pérez et al. 2020).   
 
In support of the antioxidant properties, we found a decrease in Hb1Ac in two of the eight studies 
( Xu et al. 2020; Hsu et al. 2002).  Hb1Ac is a known marker associated with increased oxidative 
stress (Palem and Abraham 2015).  In addition, we observed in one study that treatment with 
Dioscorin resulted in a decrease in systolic blood pressure possibly via angiotensin converting 
enzyme and vasorelaxation (Shih et al. 2015; Hsu et al. 2002).  Many studies have implicated 
oxidative stress in hypertension, as reactive oxygen species (ROS) influence vascular, renal and 
cardiac function and structure (Loperena et al. 2017). Further evidence of antioxidant/anti-
inflammatory properties arises for the fact that yam and/or extract can restores the activity of the 
Phosphoinositide 3 kinase/Protein Kinase B (Akt) and PPAR pathways, both known to be supressed 
in diseases associated with oxidative stress and inflammation (Li et al. 2019).  Additionally, Cai et al. 
(2018) reported that Sanggua Drink extract, which consists of Discorea, might alleviate insulin 
resistance in HFD fed rodents via the induction of the PI3K/Akt signalling pathway.  
 
The antioxidant/inflammatory properties of yam and/or its extracts may be due to the high phenolic 
and flavonoid content (Obidiegwu et al. 2020); these phenolic and flavonoids can reduce ROS and 
reactive nitrogen species (RNS) protecting pancreatic β-cells disruption (Zraika et al. 2006). Indeed, 
dioscorin has both dehydroascorbate reductase and monodehydroascorbate reductase 
activity enabling the generation of ascorbate which in turn to reduce the levels of ROS (Hou et al. 
1999), thus proposed to be a good reducing agent. Furthermore, in STZ treated mice both allantoin or 
diosgenin can increase superoxide dismutase (SOD) activity and the levels of reduced glutathione 
suggesting a reduction in oxidative stress. Moreover, allantoin treatment in STZ rats has been shown 
to reduced β-cell granulation suggesting that yam may play a potential role in protecting β-cells 
function and preventing granulation.  
 
Many of the studies focused on the effects of yam and/or its extract on diabetes have investigated the 
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yam and/or its extracts have direct effect on the pancreatic β-cells or other cell types is limited, 
despite some evidence of a possible direct mechanism. Pancreatic lipase is released from the 
pancreas causing a reduction in the absorption and digestion of dietary triglyceride.  D. opposite has 
been shown to inhibit pancreatic lipase secretion to a similar level to orlistat (the only FDA approved 
drug that inhibits pancreatic lipase to prevent 30% for fat absorption) (Kim et al. 2016; Seyedan et al. 
2015; Yang et al. 2014). This could be associated with changes in lipid profile observed in five of the 
studies (Xu et al. 2020; Li et al. 2019; Cheng et al. 2019; Hashidume et al. 2018; Wu et al. 2018) and 
decrease in body weight observed by four of the studies (Xu et al. 2020; Cheng et al. 2019; Li et al. 
2019; Wu et al. 2018). Further evidence for direct effects on the pancreas is the ability of yam, 
particularly D. batatas and allantoin, to prevent the loss of pancreatic mass by protecting against loss 
of islets, structural damage and atrophy in STZ-HFD mice (Ma et al. 2020; de Salgado Rêgo et al. 
2014); however, this effect could potentially be indirect via amelioration of inflammation and 
oxidative stress, thus warrants further studies. There is also evidence that yam and/or its extracts 
improves glycaemia via improvements in adipose and muscle tissue.  Dioscin and D. batatas 
administration decreases visceral adipose tissues and lipid profile, although this is thought to be via 
the improvements in inflammation. Interestingly there is evidence of direct effects on muscle by Niu 
et al. (2010), administration of allantoin improved glucose uptake in skeletal muscle isolated from 
STZ-diabetic rats, possibly via increased translocation of glucose transporter (GLUT) 4, leading to 
increased MCR as suggested by Sato et al. (2017).  Furthermore, administration of D. batatas or 
allantoin in STZ-diabetic rodents increased microfiber number and area.  It is well known that insulin 
resistance is manifested by a decrease in insulin stimulate glucose uptake in skeletal muscle. 
Nonetheless, the mechanism by which yam and/or extracts influences this is unknown and warrants 
further investigation.  
 
Limitation  
While all the studies identified in this review and others conducted in STZ-rodents agree that 
consumption of the various yam and/or extracts improve diabetic outcomes, there are some 
limitations to the study. These include not being able to agree on one species of yam or extract, or 
specific dose or length of consumption. Furthermore the data extracted from the studies was 
descriptive and not actual values therefore a meta-analysis was not possible. However, the biggest 
limitation of this study is the lack of human studies.  These are required to determine whether the 
effects observed in animal studies can be translated, moreover, allow us to assess whether 
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whether the process of cooking yam alters glycaemia and finally to understand whether lifestyle and 
habitual diet could influence the effects observed.  
 
Conclusion  
In summary yam and its extracts have the potential to act as functional foods in the treatment of 
T2DM in numerous ways. However further studies are required to understand potential mechanisms 
particularly in understanding the molecular pathways associated with insulin and glucose in the 
various important tissues (pancreas, muscle, adipose tissue) and to understand whether these are 
direct or indirect. Furthermore, humans studies are required alongside studies comparing yam to 
similar to reliably inform dietetic practice, guidelines and policy makers. 
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Cheng et al., 2019           Fair 
Li et al., 2019           Fair 
Wu et al., 2018           Fair 
Hashidume et al., 
2018 
          Fair 
Sato et al., 2017           Fair 
Shih et al., 2015           Fair 
Moon et al., 2014           Fair 
Kim et al., 2012           Fair 
Hsu et al., 2007           Fair 
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   Diabeti
c 
Control        
Xu et al., 
2020 




















- FBG, OGTT, 
HbA1c 
- IL, HOMA-IR, 
ISI, ITT 
- weight 
- TC, TG, LDL, 
HDL, FFA 














CYP Orally  
– OD/ 8wks 
14 wks - FBG 
- ITT 
- weight 
- TC, TG, LDL, 
HDL 
-  Alcohol 
extraction using 
water bath 
- DdH2O used for 
washing 
Li et al., 
2019 
 









– for 12wks 
12 wks - FBG 
- IL, HOMA-IR, 
Adipo-IRI 
- weight 
- TC, TG, FFA 
- TF, adiposity 
index 
- Not reported 
Wu et al., 
2018 







- OD/ 19wks 
19 wks - OGTT 
- weight 
- Homogenised 
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6 mice 6 mice  - TC, TG, LDL - eluted with NaCl 
& dialysed with 
deionised water  
Hashidume 
et al., 2018 





























Sato et al., 
2017 









diet with ad 
libitum 
access 
8 wks - FBG 
- MCR 
- weight 
- Not reported 
Shih et al., 
2015 










- OD/ 5wks 
10 wks - OGTT 
- weight 
- SBP/DBP 
- Not reported 
Moon et 
al., 2014 



















- OD/ 12wks 
12 wks - FBG 
- weight 
- 50% aqueous 
ethanol. 
- at room 
temperature for 
48hrs. 
- Filtered and 
concentrated.  
Kim et al., 
2012 











- OD/ 7wks 
12 wks - FBG, OGTT 
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- filtered and 
concentrated. 
Hsu et al., 
2007 















through water  
4 wks - FBG, IPTT, 
HbA1c 
 
- Purchased from 
Shen Chang 
Pharmaceutical 
Co., Ltd.  
RCT: randomised control trial; HFD: high fat diet; MW: male Wister; D.: Dioscorea; CYP: Chinese yam polysaccharides; OD: once daily; wks: 
weeks; FBG: fasting blood glucose; OGTT: oral glucose tolerance test; HbA1C: glycated haemoglobin; IPTT: intraperitoneal glucose tolerance 
test; IL: insulin level; HOMA-IR: Homeostatic Model Assessment for Insulin Resistance; ISI: insulin sensitivity index; ITT: insulin tolerance 
test; IGR: insulin-glucose ratio; MCR: metabolic clearance rate; adipo-IRI: adiposity insulin resistance test; TC: total cholesterol; TG: 
triglyceride; LDL: low density lipoprotein; HDL: high density lipoprotein; FFA: free fatty acids; TF: total fat; WAT: white adiposity tissue; 
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Table 3: Effects of yam consumption on glycaemic parameters measured in the selected studies.   
Article Yam/ 
extract 


















    FBG GTT         





























































   ↓* 
↓** 
↓** 





80mg/kg  30mins   
↓** 
60mins   
↓** 
90mins   
↓** 
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50mg/kg  0-120mins 
↓* 
        










         










 ↓* ↓*      



















       








       NS 
↓* 
 












      ↑*   
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Arrows indicate direction of change; *, p< 0.05; **, p<0.01; NS: Not significant, HFD: high fat diet; FD: fructose diet; ND: normal diet; FBG: 
fasting blood glucose, GTT: glucose tolerance test, HbA1c; IGR: insulin-glucose ratio, ISI: insulin sensitivity index, MCR: metabolic clearance 













, on 23 Sep 2021 at 08:56:44 , subject to the Cam
bridge Core term






                                               Accepted manuscript 
 
 
Table 4: Effects of yam consumption on parameters associated with T2DM measured in the selected studies. 
Article Yam/ 
extract 































































      
Li et al., 2019 
 















       
Wu et al., 2018 
Dioscorin 
 
HFD mice 80mg/kg ↓* NS ↓* ↓*         
Shih et al., 2015 
 
HFD rats 50mg/kg NS      SBP ↓* 
DBP 
NS  
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2014 mice 100mg/kg NS 
Kim et al., 2012 DA-9802 HFD mice 100mg/kg NS            







D. 4.2 mg/kg 
            
Cheng et al., 
2019 CYP 








































NS NS           
Arrows indicate direction of change; *, p< 0.05; **, p<0.01; NS: Not significant; HFD: high fat diet; FD: fructose diet; ND: normal diet; WT: change 
in body weight, TG: Triglyceride, TC: total cholesterol, LDL: Low density lipoproteins, HDL: High density lipoproteins, BP: blood pressure, SBP: 
Systolic blood pressure, DBP: Diastolic blood pressure, Lpn: Leptin, IL – interleukin, MMP: Matrix metalloproteinases, NF-Kβ: nuclear factor kappa-
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